Literature DB >> 26777152

Colorectal clinical trials: what is on the horizon?

Daniel H Ahn1, Richard M Goldberg1.   

Abstract

Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

Entities:  

Keywords:  colorectal cancer; immunotherapy; next-generation sequencing; targeted therapy

Mesh：

Year:  2016        PMID： 26777152      PMCID： PMC4976598          DOI： 10.2217/fon.15.327

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  56 in total

1.  Reovirus infections in human volunteers.

Authors:  L ROSEN; H E EVANS; A SPICKARD
Journal:  Am J Hyg       Date:  1963-01

2.  Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.

Authors:  Van Morris; Michael J Overman; Zhi-Qin Jiang; Christopher Garrett; Shweta Agarwal; Cathy Eng; Bryan Kee; David Fogelman; Arvind Dasari; Robert Wolff; Dipen Maru; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2014-06-23       Impact factor: 4.481

3.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

4.  Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

Authors:  Timothy J Price; Jennifer E Hardingham; Chee K Lee; Andrew Weickhardt; Amanda R Townsend; Joseph W Wrin; Ann Chua; Aravind Shivasami; Michelle M Cummins; Carmel Murone; Niall C Tebbutt
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

5.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.

Authors:  R Dolcetti; A Viel; C Doglioni; A Russo; M Guidoboni; E Capozzi; N Vecchiato; E Macrì; M Fornasarig; M Boiocchi
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

6.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

7.  Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

Authors:  Sandra Misale; Sabrina Arena; Simona Lamba; Giulia Siravegna; Alice Lallo; Sebastijan Hobor; Mariangela Russo; Michela Buscarino; Luca Lazzari; Andrea Sartore-Bianchi; Katia Bencardino; Alessio Amatu; Calogero Lauricella; Emanuele Valtorta; Salvatore Siena; Federica Di Nicolantonio; Alberto Bardelli
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

8.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

9.  Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Authors:  Lukas Baitsch; Amandine Legat; Leticia Barba; Silvia A Fuertes Marraco; Jean-Paul Rivals; Petra Baumgaertner; Céline Christiansen-Jucht; Hanifa Bouzourene; Donata Rimoldi; Hanspeter Pircher; Nathalie Rufer; Maurice Matter; Olivier Michielin; Daniel E Speiser
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

10.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.